Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 14, 2012, Pages 5364-5369

  Kubicek, Stefan ^a,b,c   Gilbert, Joshua C ^b   Fomina Yadlin, Dina ^a,b,d   Gitlin, Alexander D ^b,f   Yuan, Yuan ^a,b,d   Wagner, Florence F ^b   Holson, Edward B ^b   Luo, Tuoping ^b   Lewis, Timothy A ^b   Taylor, Bradley ^b   Gupta, Supriya ^b   Shamji, Alykhan F ^b   Wagner, Bridget K ^b   Clemons, Paul A ^b   Schreiber, Stuart L ^a,b,e  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d HARVARD UNIVERSITY   (United States)

^e HARVARD UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Beta cell biology; Chemical epigenetics; Cholesterol pathway; Gene regulation; Histone modification

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ABEXINOSTAT; AMI 1; ANILIDE; APICIDIN; BELINOSTAT; BENZAMIDE DERIVATIVE; BIX 1294; BRD 5298; BRD 6929; BRD 8451; BRD 9773; BRDA 94377914; BRDK 17311666; BRDK 22912318; BRDK 28115298; BRDK 62233722; BRDK 68338451; BRDK 90919562; BRDK 92415738; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; HYDROXAMIC ACID; MCGD 0103; PANOBINOSTAT; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR; PYROXAMIDE; RG 0108; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANIMAL CELL; ARTICLE; CELL LINE; CHROMATIN; CONTROLLED STUDY; DRUG EFFECT; ENDOCRINE CELL; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

CELL LINE; CHROMATIN; DOWN-REGULATION; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; PANCREAS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84859463823     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201079109     Document Type: Article

References (46)

1. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080. (Pubitemid 32758077)
2. Schreiber SL, Bernstein BE (2002) Signaling network model of chromatin. Cell 111: 771-778. (Pubitemid 36106399)
3. Bernstein BE, Meissner A, Lander ES (2007) The mammalian epigenome. Cell 128: 669-681. (Pubitemid 46273573)
4. Chi P, Allis CD, Wang GG (2010) Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10:457-469.
5. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351-1356.
6. Campas-Moya C (2009) Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 45:787-795.
7. Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15: 3938-3946.
8. Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243.
9. Tang W, Luo T, Greenberg EF, Bradner JE, Schreiber SL (2011) Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett 21:2601-2605.
10. Zhou Q, Melton DA (2008) Extreme makeover: Converting one cell into another. Cell Stem Cell 3:382-388.
11. Collombat P, et al. (2009) The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell 138:449-462.
12. Haumaitre C, Lenoir O, Scharfmann R (2008) Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol 28:6373-6383.
13. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600-608.
14. Methot JL, et al. (2008) Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 18: 973-978. (Pubitemid 351179353)
15. Jones P, et al. (2006) A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 16:5948-5952. (Pubitemid 44755303)
16. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A (2005) Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1:143-145.
17. Iwasa E, et al. (2010) Total synthesis of (+)-chaetocin and its analogues: Their histone methyltransferase G9a inhibitory activity. J Am Chem Soc 132:4078-4079.
18. Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC (2009) The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal 11:1097-1106.
19. Kubicek S, et al. (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25:473-481. (Pubitemid 46206139)
20. Chang Y, et al. (2009) Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 16:312-317.
21. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H (2008) Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies. Cancer 112:2341-2351.
22. Yoo CB, Cheng JC, Jones PA (2004) Zebularine: A new drug for epigenetic therapy. Biochem Soc Trans 32:910-912. (Pubitemid 39655501)
23. Brueckner B, et al. (2005) Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65: 6305-6311. (Pubitemid 40994416)
24. Cheng D, et al. (2004) Small molecule regulators of protein arginine methyltransferases. J Biol Chem 279:23892-23899. (Pubitemid 38725246)
25. D'Ambra R, Surana M, Efrat S, Starr RG, Fleischer N (1990) Regulation of insulin secretion from beta-cell lines derived from transgenic mice insulinomas resembles that of normal beta-cells. Endocrinology 126:2815-2822. (Pubitemid 20216530)
26. Hamaguchi K, Leiter EH (1990) Comparison of cytokine effects on mouse pancreatic alpha-cell and beta-cell lines. Viability, secretory function, and MHC antigen expression. Diabetes 39:415-425.
27. Amit I, et al. (2009) Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 326:257-263.
28. Stadtfeld M, et al. (2010) Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465:175-181.
29. Smyth GK (2005) Limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor, eds Gentleman RC, Carey VJ, Huber W, Irizarry RA, Dudoit S (Springer, New York), pp 397-420.
30. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article 3.
31. Lamb J, et al. (2006) The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935. (Pubitemid 44497995)
32. Bernstein BE, Tong JK, Schreiber SL (2000) Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 97:13708-13713.
33. Dejligbjerg M, et al. (2008) Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer 7:70.
34. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273. (Pubitemid 36792858)
35. Subramanian A, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550. (Pubitemid 41528093)
36. Jacobs NL, et al. (1997) Analysis of a Chinese hamster ovary cell mutant with defective mobilization of cholesterol from the plasma membrane to the endoplasmic reticulum. J Lipid Res 38:1973-1987. (Pubitemid 27468006)
37. Vedadi M, et al. (2011) A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 7:566-574.
38. Fryirs M, Barter PJ, Rye KA (2009) Cholesterol metabolism and pancreatic beta-cell function. Curr Opin Lipidol 20:159-164.
39. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: A novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56:2328-2338. (Pubitemid 47358240)
40. Ellis L, et al. (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510.
41. Glaser KB, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
42. Miyanaga A, et al. (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: Development of a molecular predictive model. Mol Cancer Ther 7:1923-1930.
43. Peart MJ, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702. (Pubitemid 40354674)
44. Boulias K, Talianidis I (2004) Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression. Nucleic Acids Res 32: 6096-6103. (Pubitemid 40074004)
45. Fang S, et al. (2007) Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism. Mol Cell Biol 27:1407-1424. (Pubitemid 46239822)
46. Reich M, et al. (2006) GenePattern 2.0. Nat Genet 38:500-501.